Clinical Trials Logo

Clinical Trial Summary

The purpose of our study is to determine, using a prospective, randomized-controlled trial, the economic viability and clinical outcomes associated with patient-specific instrumentation (PSI) for total knee arthroplasty in an obese patient population.


Clinical Trial Description

This is a randomized, blinded study. Following REB approval, eligible patients electing to undergo TKA will be identified by either the PI or co-investigators, and approached in an orthopaedic outpatient clinic to discuss enrolment into the study. Patients will be enrolled if they meet the prerequisite inclusion criteria and have signed an informed consent. Patients will then be randomized to undergo a TKA using PSI, or a conventional TKA. The randomization sequence will be computer generated using blocks of five. Preoperative Assessment At baseline, patients will complete a Knee Society Score (KSS), Short-Form 12 (SF-12) Questionnaire, and Western and McMaster University Osteoarthritis Index (WOMAC) questionnaire, and the European Quality of Life Scale Index (EQ-5D). The EQ-5D is a validated, reliable, and feasible outcome measure that provides a utility index. This utility index allows quality adjusted life years to be calculated following an intervention. The questionnaire is a 5-item standardized generic measure of health related quality of life that includes domains of mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each item is scored using a 3-point response scale and each combination of response choices describes a health state (resulting in 243 possible health states). Each health state can then be converted to a utility value ranging from 0 (worst) to 1.0 (best) using existing preference valuation data[22]. It has been valuated in both Canadian and American populations for use in assessing health-related quality of life [23, 24]. We will then calculate each patient's quality-adjusted life year (QALY). QALYs incorporate both length of life and quality of life into a single measure and are calculated by multiplying the utility value by the length of time spent in that health state. Additionally, a clinical assessment will be completed, including knee range of motion, ligamentous assessment, and evaluating for soft tissue contractures. Finally, patients will have 3-foot coronal and sagittal standing radiographs of their lower extremities at our institution. The standing mechanical axis of the involved limb will then be calculated. Skyline views will also be performed as part of the radiographic analysis. In order for appropriate preoperative planning, patients randomized to PSI will undergo a computed tomography (CT) scan of the surgical limb using the TruMatch TM scanning protocol. Following modifications made by the treating surgeon, the personalized patient instruments will be manufactured in standard fashion. Intraoperative Assessment On the day of surgery, patients will receive either a spinal or general anesthetic based on recommendations from an anesthetist, or personal preference. A non-sterile tourniquet will be applied to the operative limb. A mid-line skin incision followed by a medial parapatellar arthrotomy will be used for exposure. The femoral and tibial cuts will be made using conventional instrumentation in the control group, or the TruMatch TM Personalized Solutions Instruments in the treatment group. Soft tissue balancing, including releases and removal of osteophytes, will be performed at the discretion of the surgeon. The Attune TM components will be implanted using cement fixation. At the time of cementing the implants, patients will receive a parenteral weight-based dose of tranexamic acid (20 mg /kg), provided that there are no contra-indications. Prior to closure, patients will receive an intra-articular injection of an anesthetic cocktail. The parapatellar arthrotomy and subcutaneous tissue and skin will be closed in standard fashion. Post-operatively, patients will receive deep-vein thrombosis prophylaxis for 14-days post-operatively. They will also receive 24 hours of post-operative parenteral antibiotics. They will be assessed by physiotherapy, with weight-bearing and range of motion exercises beginning on post-operative day 0. Patients will be discharged from hospital once they have reached appropriate rehabilitative milestones outlined by our institution. Postoperative Assessment Patients will have routine follow-up with their surgeon at 2-, 6-, and 12-weeks, followed by 1-year and every other year thereafter. Three-foot coronal and full-length sagittal standing radiographs, as well as skyline views of the involved knee, will be taken at the 1-year postoperative visit. We will calculate the mechanical axis of the operative limb based on this postoperative radiographic assessment. The patients will complete the KSS, SF-12, WOMAC, and EQ-5D questionnaires at their 6-week, 12-week, and 1-year visits. These outcome questionnaires will be collected prospectively at 5-years and 10-years post-operatively through our institution's database. Assessors of both clinical outcomes and mechanical axis will be blinded to surgical intervention (conventional instrumentation versus PSI TKA). Patients will also receive a health care resource use diary to complete between follow-up intervals in order to collect outpatient direct and indirect costs associated with TKA. Costs Our institution's costs-accounting department will provide information regarding operating room costs, implant costs, and costs associated with routine care such as nursing, medications, and investigations. Physician-related costs will be acquired through Ontario Health Insurance Plan billing protocols. The outpatient cost analysis diary will capture direct, non-medical costs associated with TKA (see Appendix C). The data will be reported in Canadian dollars for the fiscal year in which the in-hospital cost data was derived. A sample database we are currently employing in an unrelated study can be provided if required. Cost-Utility Analysis Incremental Cost-Utility Ratio (ICUR) The ICUR represents the ratio of incremental cost to incremental utility. The incremental cost represents the additional cost of the PSI group compared to the conventional group. The costs will include all direct (operating room, hospital stay, rehabilitation, medications, investigations) and indirect costs (informal care, time lost to productivity). Similarly, the incremental utility is the mean difference in QALY between groups. Net Benefit Regression We will use the net benefit regression (NBR) framework to estimate the incremental net benefit (INB) of PSI [25]. An intervention is considered to be cost-effective if the INB is greater than zero. The net benefit regression method also provides a means to adjust for any potentially confounding factors and therefore allows greater statistical efficiency and provides a more precise estimate of the INB. We will include the following covariates in our regression models: baseline utility score, severity of osteoarthritis, age and number of comorbidities. To characterize the statistical uncertainty around our estimate of INB we will calculate 95% confidence intervals, and a cost-effectiveness acceptability curve (CEAC). Modeling To determine the cost-effectiveness of a new intervention, an economic decision model is appropriate when there are multiple existing sources of evidence to answer a question (e.g. randomized trials, cohort studies, registries, etc.) or to forecast the costs and/or outcomes beyond the follow-up period of the clinical trial. Given that PSI is a relatively new technology, there is no long-term data available to accurately determine the survival of the implant or the rate of revision. To accurately answer this question, we will prospectively follow the cohort long-term to determine survival rates of the implant. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02177227
Study type Interventional
Source Lawson Health Research Institute
Contact
Status Active, not recruiting
Phase N/A
Start date August 2014
Completion date August 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2